Who Paid My Doc
Bonita Libman
Rheumatology Burlington, VT Medical Doctor
NPI 1194830083 CMS profile 368937
111 Colchester Ave, East Pavilion Level 5 Rheumatology, Burlington, VT 05401
General payments
$44
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$36,463
Through program year 2019, Bonita Libman of Burlington, VT is reported in the CMS Open Payments database as having received $44 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,463 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 5th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $44 | 1 |
Beside peers
- Bonita Libman
- Rheumatology median
- Middle half of Rheumatology
- National median
In program year 2025, general payments to Bonita Libman were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.
Show as a table
| Year | Bonita Libman | Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $44 | $744 | $153–$2,687 | $163 |
| 2020 | $0 | $462 | $98–$2,027 | $114 |
| 2021 | $0 | $531 | $101–$2,153 | $132 |
| 2022 | $0 | $627 | $125–$2,303 | $149 |
| 2023 | $0 | $741 | $145–$2,524 | $160 |
| 2024 | $0 | $830 | $166–$2,660 | $164 |
| 2025 | $0 | $903 | $171–$2,775 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 34 drugsPart D claims
1,642
Drug cost
$2,707,445
Branded share of claims
41.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 80 | $636,222 | |
| Humira(Cf) Pen Adalimumab | Brand | 74 | $597,208 | |
| Skyrizi Pen Risankizumab-Rzaa | Brand | 14 | $278,582 | |
| Actemra Actpen Tocilizumab | Brand | 55 | $242,895 | |
| Cimzia (2 Pack) Certolizumab Pegol | Brand | 21 | $206,275 | |
| Tremfya Guselkumab | Brand | 11 | $138,144 | |
| Xeljanz Xr Tofacitinib Citrate | Brand | 18 | $115,371 | |
| Rinvoq Upadacitinib | Brand | 17 | $104,836 | |
| Xeljanz Tofacitinib Citrate | Brand | 14 | $92,486 | |
| Otezla Apremilast | Brand | 16 | $90,950 |
The 10 drugs with the highest cost, of 34 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 21 billing codesPaid by Medicare
$27,354
Medicare patients
270
Services billed
503
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 60% | |
| Osteoporosis | 24% | |
| Depression | 21% | |
| Diabetes | 20% | |
| Ischemic heart disease | 17% | |
| Chronic kidney disease | 17% | |
| Atrial fibrillation | 13% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Rheumatology in Vermont
Practitioners in the same specialty and state, ranked by reported value.
All Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Vermont
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.